Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2021-08-11 Director's Dealing
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-08-11 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-11 English
Grant of Options
Director's Dealing Classification · 1% confidence The document is a formal notification of share option grants to Persons Discharging Managerial Responsibilities (PDMRs) at MaxCyte, Inc. It explicitly follows the standard regulatory format for 'Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities', which is a classic Director's Dealing (DIRS) filing. It details the names, positions, transaction nature (grant of options), and specific volumes for each director/officer.
2021-08-10 English
License with Sana Biotechnology
Regulatory Filings Classification · 1% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service) announcing a new clinical and commercial license agreement between MaxCyte, Inc. and Sana Biotechnology. It details a strategic business development event rather than a financial report, board change, or shareholder meeting. Since it is a general regulatory announcement regarding company operations that does not fit into more specific categories like M&A or capital updates, it is classified as a Regulatory Filing (RNS).
2021-08-09 English
S-8
Registration Form
2021-08-05 English
Amendments to Bylaws
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from MaxCyte, Inc. regarding the filing of amended and restated Bylaws with the SEC. It serves as a notification that the company has updated its corporate governance documents and provides a link to where the full document can be accessed. Since it is a short announcement regarding the publication/filing of a document rather than the document itself, it falls under the 'Report Publication Announcement' category.
2021-08-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.